Pharmaceutical Market Of Ukraine Research Articles

Analysis of the assortment and economic affordability of noоtropic drugs

Aim. To analyze the range and assess the economic availability of nootropic drugs at the Ukrainian pharmaceutical market in 2018.
 Materials and methods. The study object was information about nootropic drugs available at the pharmaceutical market of Ukraine in 2018 based on the data of the “PharmXplorer” analytical system of the information retrieval company “Morion”. The study included drugs used for the treatment of cerebrovascular diseases from the N06B X pharmacotherapeutic group (according to the ATC classification) – “Other psychostimulative and nootropic drugs”. An indicator of the adequacy of solvency (Ca.s.) was calculated using the data taken on the prices of drugs and the average level of wages for 2018.
 Results. At the Ukrainian pharmaceutical market in 2018 a wide range of nootropic drugs was presented. The range of retail prices per drug pack was significant, indicating the possibility of a doctor and a patient to choose the drug taking into account its efficacy, safety and affordability. Most trade names of nootropics (52 %) were registered as oral dosage forms, being compliant for patients with chronic cerebral circulatory disorders. 48 % were injectable and infusion drugs, which were topical for acute ischemic attack.
 Conclusions. It was found that in 2018 drugs containing piracetam, vinpocetine, gamma-aminobutyric acid (GABA) and its derivatives, most drugs based Phenibut (84.6 % of TN) and citicoline (68 % of TN) were highly available to the consumer. Most of the injectable dosage forms of nootropics based on hydrolyzates and tissue derivatives were readily available (50 % of TH) for the average consumer in Ukraine. Considering a fairly wide range of nootropic drugs and the economic availability of most of them the principle of superiority of clinical efficacy, safety and affordability should be the basis for creating and developing new nootropic drugs.
 Key words: nootropic drugs; assortment; economic affordability; Ukrainian pharmaceutical market.

The marketing analysis of the market of medicines for the treatment of the wound process and burn disease at the hospital stage in the military personnel

Aim. To summarize the list of medicines that can be used at various stages of the treatment of burn disease and wound healing at the hospital stage in the military personnel; conduct the marketing analysis of the Ukrainian market of these medicines in order to determine the feasibility of creating an ointment for the treatment of inflammatory skin diseases and burns.
 Materials and methods. The study objects were the “State Register of Medicinal Products of Ukraine” information and search system and the Compendium. When conducting our studies the following scientific and system-review methods of the information search were used: bibliographic, documentary, content analysis, comparison method, system analysis, marketing research.
 Results. As a result of the study of the range of drugs for wound healing presented at the pharmaceutical market of Ukraine, it has been found that 64 % are drugs of the Ukrainian production, foreign drugs are 36 %. The distribution of soft drug forms registered in Ukraine has been carried out by pharmacological groups; it has been found that the percentage of antimicrobial and antifungal drugs is almost the same (15.8 % and 15.2 %, respectively). Steroidal anti-inflammatory drugs predominate over nonsteroidal ones (14.9 % and 11.4 %, respectively). The studies conducted have shown that at the domestic market there are many drugs of foreign production, which have no Ukrainian analogs. The marketing research has shown that combined drugs are more effective for the treatment of burns. They act simultaneously in several directions and facilitate the healing process. Among the drugs considered combined medicines occupy 42 %, while the share of monocomponent drugs is 58 %. The amount of synthetic drugs is 88 % and significantly exceeds the number of herbal medicines (12 %).
 Conclusions. The concept and methodology for the treatment of burns are summarized. It has been determined that the drugs of choice are complex soft drug forms. As a result of the marketing research on the structure and nomenclature of soft drug forms it has been found that at the domestic pharmaceutical market soft drug forms of foreign production is 36 %, and domestic ones – 64 %. It has been determined that the number of drugs for local wound healing is about 6 % of the total range of soft drug forms and presented mainly by monocomponent drugs (58 %). The analysis of the range of drugs with the anti-burn and antiseptic action by dosage forms has shown that ointments are the largest share – 67%, drugs in the form of creams – 18%.
 Key words: marketing analysis; servicemen; burn disease; wound process; hospital stage of treatment.

The state regulation of the economic activities in domestic pharmacy: regulatory aspect

In modern working conditions, a pharmacist has insufficient knowledge of regulatory documents regulating the activities of the pharmaceutical industry. Thus, there is a need to provide informational assistance to the pharmacist by systematizing the current legal documents.
 Aim. To scientifically generalize legal acts on the state regulation of the business entity in pharmacy in Ukraine.
 Materials and methods. Regulatory legal acts regulating the process of the state regulation of the activity of an economic entity in pharmacy in Ukraine, and such methods as content analysis, generalization were used.
 Results. As a result of the content-analysis it has been found that state supervision (control) of the pharmaceutical market of Ukraine is performed by the following state structures: the State Service of Ukraine for Medicines (Drugs) and Drug Control, the State Service of Ukraine for Food Safety and Consumer Protection, the State Fiscal Service, the State Labor Service of Ukraine, the State Emergencies Service of Ukraine.
 Conclusions. When conducting the content-analysis it has been found that the legal documents regulating the process of pharmaceutical care provision in Ukraine are the Laws of Ukraine “On licensing of the economic activities”, “On consumer protection”, “On labor protection”. A graphic model of the state regulation of the business entity’s activity in Ukraine has been also created.
 Key words: state regulation; business entity in pharmacy; regulatory legal acts; content-analysis.

Research of the range of medication for pulmonary hypertension pharmacotherapy in adults in the pharmaceutical market of Ukraine

Pulmonary hypertension (PH) is a group of rare diseases, malignant in nature, without optimal treatment quickly lead to death. Such patients usually require expensive, continuous and lifelong treatment. Therefore, the study of the assortment structure of drugs used for the treatment of drugs in adults in the domestic market of medicines (drugs) is very relevant.
 The aim of the study was to analyze the range of drugs for the pharmacotherapy of drugs in the modern pharmaceutical market of Ukraine. The object of the study was information on drugs registered in Ukraine, which are included in the protocol of treatment of patients with PH. In the process of research, system-review, graphic, documentary and marketing research methods were used. The result of the study showed that in the pharmaceutical market of Ukraine there are no drugs based on INN Epoprostenolum, Treprostinil, Beraprostum, Selexipagum, Macitentan, Tadalafilum, Vardenafilum, recommended by the Adapted clinical guidelines for the treatment of adult patients with PH and Unified clinical protocol of emergency, primary, secondary (specialized) and tertiary (hypersensitivity) medical care «Pulmonary hypertension in adults». Simultaneously INN Rivaroxabanum, Apixabanum, Dabigatranum etaxilatum, Iloprostum, Torasemide, Bosentanum, Ambrisentanum, Riociguat are included in the Unified clinical protocol of emergency, primary, secondary (specialized) and tertiary (hypersensitivity) medical care «Pulmonary hypertension in adults» and tertiary (hypersensitivity) Ukraine, however, are not included in the National List of Essential Medicines, which legally limits the possibility of their purchase by health care institutions for budget funds, but only centrally by the Ministry of Health of Ukraine. The structure of drugs for the treatment of PH in adults according to the ATX classification indicates that the largest share have groups С03С – Diuretics – 36.47%, С08С – Selective calcium antagonists with a predominant effect on blood vessels – 32.94%.
 The import dependence of the pharmaceutical market of medication for PH treatment is relatively high and constitutes about 60% of the number of trade names of medication for PH pharmacotherapy that needs research in the directions of its expansion through import substitution and legislative settlement of questions of improving the accessibility of this medication group.

Comparative studies of the kinetics of dissolution of medicines on the basis of clopidogrel

Generic medicines occupy dominant positions both in the pharmaceutical market of Ukraine and in industrial production by domestic pharmaceutical enterprises. The use of generic drugs in medical practice is of significant medical and social importance for expanding the accessibility of the general population to essential drugs. In Ukraine, more than twenty generic medicines based on clopidogrel, both foreign and domestic, are registered. All generic drugs containing clopidogrel bisulfate must comply with pharmaceutical bisulfate must comply with pharmaceutical equivalence, the kinetics of release of the active pharmaceutical ingredient using the Dissolution test in vitro, and pharmacokinetic parameters in vivo.
 The aim of the work was to carry out comparative studies of the dissolution kinetics of four samples of generic drugs based on clopidogrel with the dissolution kinetics of the original drug Plavix®, to evaluate the similarity factor of dissolution profiles and to determine the effect of biopharmaceutical factors on the equivalence of generics. Comparative studies of the kinetics of dissolution were carried out by the in vitro method according to the «Dissolution» test using a device with a blade with a
 rotation speed of 50 rpm, a dissolution medium with a pH value of 2.0 in a volume of 900 ml at a temperature of 37 ± 1 °C. The determination of the quantitative content of clopidogrel, which passed into the dissolution medium, was carried out by the method of adsorption spectrophotometry in the ultraviolet region at a wavelength of
 about 240 ± 2 nm. Based on the data obtained, the dissolution profiles of the original drug Plavix® and the studied samples of generic drugs were constructed, the similarity of which was assessed by the value of the similarity factor. According to the research results, it was found that one sample of the generic drug proved its equivalence by the in vitro method to Plavix®, and three other samples of generics had differences in dissolution kinetics in comparison with the original drug. Biopharmaceutical factors were analyzed that could affect the dissolution kinetics of the studied generic drugs, from which the physicochemical characteristics of clopidogrel bisulfate, the qualitative and quantitative composition of excipients and the features of the technological process were determined.
 Thus, on the basis of the comparative studies of the dissolution kinetics of drugs based on clopidogrel, generics were found that did not correspond to the in vitro equivalence according to the Dissolution test to the original drug, which could be due to the influence of a combination of biopharmaceutical factors.

The analysis of the drug assortment of immunostimulants presented at the Ukrainian market

Aim. To analyze the registered medicines of the group of immunostimulants in order to determine the feasibility of creating and organizing the production of new drugs based on natural clays, in particular green and yellow clays.Materials and methods. The list of medicinal products compiled from official sources of information was used in the work; it was processed by the methods of generalization, systematization, graphical method, as well as the methods of comparative and structural analysis.Results and its discussion. The analysis of the Ukrainian pharmaceutical market concerning the range of the registered immunostimulants has been performed. Structuring of the selected list of medicines by the ATC-classification, origin, composition, production characteristic and dosage form type has been carried out. By production basis the majority of medicines are of domestic production (63.58 %). It has been determined that drugs of the segment studied are produced in solid and liquid dosage forms. Solutions for injection are prevalent at the domestic pharmaceutical market, and the range of solid dosage forms is under developed. At the pharmaceutical market, there are no drugs of this group with natural clays, in particular yellow and green clays.Conclusions. The absence of immunostimulants based on natural clays at the Ukrainian market has been proven; it indicates the feasibility of introducing new domestic drugs with the immunostimulating action on the basis of natural clays, in particular yellow and green clays, to the market.

СИНЕРГЕТИЧНІ МЕТОДИ В ПРОГНОЗУВАННІ ДИНАМІКИ ПРОЦЕСІВ ФОНДОВИХ РИНКІВ

This article is devoted to forecasting the dynamics of processes occurring in the stock market, the methods of chaotic dynamics. Chaotic dynamics is one of the areas of synergetics. Although there are many effective methods for modeling securities price forecasts, emerging stock markets are characterized by long-term stability and short-term instability. In this situation, to study the processes occurring in the markets, chaos theory can be used, which includes methods of theory of dynamical systems and fractal analysis. An example of practical implementation of this approach using neural networks for the share price of the company "Pharmacy 36 and 6" at the close of trading for 2014–2019. The company "Pharmacy 36 and 6" is a retail network of pharmacies "Lekpharm", which is actively working and developing in the pharmaceutical market of Ukraine since 2001. The initial data were obtained on the website of the holding "FINAM". Neural networks have the ability to learn. At the same time, in the process of learning there is a phenomenon similar to self-organization. This property is characteristic of chaotic systems. The most important characteristics of chaos-dynamic analysis are calculated: Hausdorff dimension and Kolmogorov entropy. Their values indicate that the studied statistical series contains a chaotic component. The algorithm of technical application of neural networks is offered in the article. The model is built using neural network technology. Some of the input parameters of the network are determined based on the analysis performed. Comparison of the results obtained on the model deviate slightly from the actual data. It could be considered. that the model is adequate and can be used in practice. Forecasting the dynamics of securities can give a certain economic effect, a specific financial benefit to the owners of securities. Synergistic methods do not always lead to a solution to a problem or task. But they lead to a deeper and more accurate understanding of reality, which allows one to give an explanation for incomprehensible phenomena, such as pre-construction stability and short-term instability. Therefore, the synergistic economic paradigm has an interest on the part of researchers and policy makers.

ПІДХІД ДО РЕКЛАМИ НОВОГО ЛІКАРСЬКОГО ЗАСОБУ З ВИКОРИСТАННЯМ МЕТОДІВ ЕКОНОМІКО-МАТЕМАТИЧНОГО МОДЕЛЮВАННЯ

The article analyzes the factors influencing the sale of innovative medicines, including the impact of advertising. The main purpose of the study is to determine the impact of advertising on an innovative drug in the pharmaceutical market of Ukraine, which was implemented through a review of recent scientific publications. The new drug is definitely an innovation. It has been studied that the spread of innovations occurs gradually among members of the social system through communication channels for their adaptation. With regard to product innovation, the process of deciding on their adaptation can be divided into five stages: knowledge, persuasion, acquisition, usage, loyalty. The economic essence of this topic is analyzed in detail, the legal framework for advertising of medicines in the media is considered and the economic-mathematical model for obtaining a relevant forecast is selected. It was also found that the Ukrainian pharmaceutical market is developing quite rapidly, but it lacks innovation. A review of pharmaceutical market threats also found that although the pharmaceutical industry is highly dynamic, it lacks innovation. During the whole period of independence, Ukraine presented only 154 medicines of innovative character. Everything else is generic drugs, in addition, mostly of dubious quality. In modern enterprises, all investments go to the modernization of technological processes, rather than the production of new original drugs. That is why foreign manufacturers have better indicators of drug imports.Any marketing costs before launching a drug are an investment. Considered the types of promotion most suitable for advertising drugs. Therefore, the most known model of diffusion of innovations, compiled by Bass, can be used to model a specific economic and mathematical problem. The economic essence of Bass's model of diffusion of innovations is investigated. The correct method of calculation of this type of model has been selected, namely the AnyLogic software environment, which is suitable for research and calculation of parameters of system dynamics models. The study predicted future sales of the drug using data from previous sales. During the research and use of the Bass innovation model, a forecast of future sales for 10 months was formed.

АУДИТ ФАСОВАНОЇ ПРОДУКЦІЇ ЛІКАРСЬКИХ РОСЛИН, ЯКІ ЗАСТОСОВУЮТЬСЯ ПРИ ЦУКРОВОМУ ДІАБЕТІ, НА ФАРМАЦЕВТИЧНОМУ РИНКУ УКРАЇНИ

Key words: marketing, medicinal plants, herbal substances, dietary supplements, pharmacy, diabetes mellitus, pharmaceutical market of Ukraine Phytotherapy is an important part of the treatment of patients with diabetes mellitus. The use of medicinal plants in complex therapy allows to reduce the dose of synthetic drugs, and it can be used as monotherapy. Today pharmacies offer a wide assortimets of medicinal plants. Considering the importance of treatment of diabetes, it is relevant to study the modern market of medicinal plants in Ukraine, which are used for the treatment and prevention of diabetes. The purpose of the work was to audit the assortment of packaged products of medicinal plants for the treatment and prevention of diabetes, which are available on the pharmaceutical market of Ukraine. Materials and methods. The literature data and the official sources of information were the material of the research. We used content analysis, marketing, graphic, comparative and summarizing analyzes. Conclusion. Considering manufacturers, type and packing weight of medicinal plants was found that the number of proposals is 310, while herbal substances, account for 42.3%. Various parts of plants (leaves, flowers, grass, shoots, fruits and so on) are used in phytotherapy for diabetes. The redundancy of assortment of medicinal plants by various domestic manufactures is observed. The herbal substances are packed in corton packs, and dietary supplements are packed in 1.5 g filter bags No. 20. Analysis of Summaries of product characteristics of herbal substances has shown that only part of them have information about therapeutic indication and pharmacological properties for treatment of diabetes. The lack of this information could be a problem for consultation by pharmacist.

Pharmaceuticals marketing researches for use in dermatology and on the pharmaceutical market of Ukraine in general (message II)

Pharmaceuticals marketing researches for use in dermatology and on the pharmaceutical market of Ukraine in general (message II)

ПРАВОВІ АСПЕКТИ ВПЛИВУ ІНТЕЛЕКТУАЛЬНОЇ ВЛАСНОСТІ НА ДОСТУПНІСТЬ ЛІКАРСЬКИХ ЗАСОБІВ В УКРАЇНІ

The right of a person to access medicines is derived from the right to health. At the time of the establishment of fundamental human rights, the issue of lack of access to medical supplies was not considered a violation of human rights. The spread of pandemics has led to the gradual recognition of the right of access to medicines. The TRIPS agreement fundamentally reformatted the discussion on access to medicines. Prior to the TRIPS Agreement, states had considerable independence in the formation and implementation of state policy in the field of intellectual property. TRIPS obliges countries to provide pharmaceutical patents. The growing influence of the international patent system has aroused widespread interest and concern about the impact on access to medicines. The Doha Declaration on the TRIPS Agreement defines the importance of the implementation and interpretation of the Agreement in the most favorable way for the protection of public health by making available to the public existing medicines and creating conditions for the production of new ones. Ukraine is on the way to creating its own legislation in the field of intellectual property. Art. 219 of the Association Agreement between Ukraine and the European Union contains provisions according to which the parties recognize the importance of the Declaration on the TRIPS Agreement in the field of health care. Positive changes in the field of intellectual property include the provisions of the Law of Ukraine «On Amendments to Certain Legislative Acts of Ukraine on the Reform of Patent Legislation» № 816-IX as of 21.07.2020. This law limited the range of objects to be patented. The implementation of these legislative changes is impossible without a proper methodology for the examination of novelty. Reforming the national system of intellectual property protection has created good preconditions for the formation of a civilized pharmaceutical market in Ukraine. Among the areas of legislation in Ukraine, there is an urgent need to form an institution of compulsory licensing. A separate area is the introduction of the pre-grant and post-grant procedures of the opposition. An important area of legislative work is the formation of a favorable domestic policy for innovation and invention in the field of medicine and biotechnology.

МАРКЕТИНГОВІ ДОСЛІДЖЕННЯ ЛІКАРСЬКИХ ЗАСОБІВ ДЛЯ ЗАСТОСУВАННЯ У ДЕРМАТОЛОГІЇ НА ФАРМАЦЕВТИЧНОМУ РИНКУ УКРАЇНИ (ПОВІДОМЛЕННЯ I)

Keywords: pharmaceutical, marketing research, medicinal product, marketing researches, active pharmaceutical ingredient, drug formulation, pharmaceutical market, wound process. The purpose of the study was to conduct complex marketing research of the current condition of the pharmaceutical market for use in dermatology to compose the well-balanced combination drugs (CD) for wound healing. Materials and methods: Conduct of complex marketing researches involved the use of general scientific, systematic, and survey research methods of informational search: bibliographical, document retrieval, content analysis, comparative approach, and system-oriented analysis. Results. The current condition of the domestic pharmaceuticals market was analysed and summed up for the availability of the Group D medicinal products according to Anatomical Therapeutic Chemical (АТС) classification system. Market dependency on import medicinal products was identified (import products share amounts to 57,8% of the market). The trends which reflect the innovation activity of the domestic pharmaceutical industry were presented in the findings. Prevailing (based on its specific density) medicinal products subgroups according to ATC classification «Corticosteroids for use in dermatology» (26,3%), «Anti-fungals for use in dermatology» (18,1%), «Antiseptics and Disinfectants» (14,1%), «Medicinal products for wound and ulcerous injuries healing» (12,7%), and «Antibiotics and chemotherapeutics» (11,5%). It was established that the main importers of the interested medicinal products groupare Germany (20,4%), India (16,2%), Poland (12,3%), Croatia (7,1%), Switzerland (6,3%), Belgium (5,2%), Austria (4,8%), and Hungary (4,2%). We found out that in the dermatology medicinal products segment, active pharmaceutical ingredients by their nature are mostly synthetic (88%), and by their composition, such medicinal products are mixed formulations with the subgroups market share between 58,5% – 76,3%. It was also shown that the optimal assortment range of modern combination drugs of dermatology medicinal products for 38 domestic producers is not yet reached. We paid attention to the perspective regarding the pharmaceutical development of new combination drugs for application therapy. Conclusions. The research of the effectiveness of different groups of medicinal products to wound healing on different stages, allowed us to conclude that the usage of imported combination effect medicinal products for wound healing is more cost-ineffective while the Ukrainian pharmaceutical market requires product differentiation and introduction of the new combined antimicrobial and anti- inflammatory effect medicinal products into production for wound healing and wound infection.

Роль профілактики дефіциту вітаміну D у поліпшенні акушерських, перинатальних та віддалених результатів

Much attention is paid to deficiencies prevention during pregnancy, since they negatively affect not only metabolic processes, including fetoplacental complex, but also the condition of the fetus, the newborn, and physical and mental development of the child in the future. Summarizing the recommendations for the use of vitamin D during pregnancy, it should be noted that the typical prophylactic dose is 400 IU/day starting from the first trimester. However, we should consider the use of corrective doses in the second and third trimesters when the fetal skeleton is growing and developing. A high dose of vitamin D (2000 IU/day) is recommended for women at high risk of developing hypertensive complications of pregnancy (a history of preeclampsia, in particular, arising before 28 weeks, arterial hypertension, chronic kidney disease), as well as pregnant women with comorbidity (systemic red lupus, rheumatoid arthritis, multiple sclerosis, cardiovascular disease, inflammatory bowel disease, oncological pathology). For women at risk of vitamin D deficiency, the recommended dose is less than 1000 IU/day. In case of confirmed vitamin D deficiency (<25-30 nmol/L), a correction dose of 2000-4000 IU/day is prescribed for 11 weeks to provide a cumulative dose of about 150,000 or 300,000 units in the second or third trimesters. Today, a sufficient number of vitamin D preparations are presented on the pharmaceutical market of Ukraine, among which one should pay attention to "Olidetrim" (Polpharma, Poland) in the form of oil solution in capsules ensuring its absorption and assimilation. Depending on the dosage, each capsule of the preparation contains 2000 IU or 4000 IU of vitamin D3 (cholecalciferol). In addition to the fat-soluble form, vitamin D preparation Aquadetrim® (Polpharma, Poland) is registered and successfully used in Ukraine. This is a unique form of vitamin D3 based on nanomycellae, which provides better absorption of vitamin D in the intestine. Key words: vitamin D, deficiency, pregnancy, fetus, prevention.

REGULATORY MECHANISMS OF UKRAINIAN PHARMACEUTICAL MARKET COMPETITIVENESS IN THE CONTEXT OF EUROPEAN INTEGRATION

The purpose of the paper is to summarize and present the differences in the competitive environment of the European Union (EU) and Ukrainian pharmaceutical markets. The method of longitudinal study allowed to detect the patterns of changes and correlations for pharmaceutical products exports and imports volumes over twenty years (2001-2020). Methodology. The research is based on the definition of the pharmaceutical market as a complex socio-economic institution that fulfills the function of pricing medical products and utilizes them to ensure health care functioning. It indicates the population’s wellbeing and requires ongoing maintenance based on needs agreement of households, economic entities, and the state. The quantitative research is based on export-to-import coverage ratio calculations with the identification of pharmaceutical products fraction in the total volume of foreign trade, including the one with the EU. The results of the paper consist in the evaluation of the competitive environment of the European Union’s pharmaceutical market and statistical assessment of Ukrainian foreign trade of pharmaceutical products. They also include the definition of the European integration influence over the Ukrainian pharmaceutical market and well-reasoned recommendations about the application of the state and trade regulation mechanisms. In the paper, we defined the distinctive features of the European countries’ pharmaceutical markets and outlined their main characteristics that have connections to the transnational corporation’s activities, common market, and high concentration. Statistical data collected over 20 years indicated the dynamic development of the Ukrainian pharmaceutical market, despite its small-scale contribution to the foreign trade turnover. The dependence of Ukraine on the foreign supplies of drugs and medications is illustrated by the multiple excesses of imports over exports, especially in the trade relationships with the EU. The EU countries are the leading importers of pharmaceutical products to the Ukrainian market. However, the share of medical supplies exports from Ukraine to the EU countries is negligible. Their key exporters are post-Soviet and developing countries. The growth in Ukraine’s export potential is inextricably linked to the expansion of the competitiveness of domestic medical supplies. Practical implications consist in the development of recommendations concerning the GMP and GDP demands realization, domestic manufacturers cooperation with the leading foreign pharmaceutical companies, the penetration of transnational companies into the Ukrainian domestic pharmaceutical market based on imports of innovative technologies, the improvement of the marketing management of the pharmaceutical products exporting. The priority factor in the growth of the competitiveness of the Ukrainian pharmaceutical market is a successful combination of state and trade regulation mechanisms. The objects of these factors are the pricing policy for material resources and finished products, the introduction of innovations, tax exemptions, and export-import quotas implementation. They also include the establishment of traffic rates that depend on the market saturation with socially significant medical supplies, budget support of the prioritized subsectors of the pharmaceutical industry, and patent protection. The expected results concern the decrease in the dependence of the Ukrainian pharmaceutical market on the foreign distribution of the raw materials and finished products and strengthening the positions of the Ukrainian manufacturers in foreign markets. Value/originality. We evaluated the competitiveness of the national pharmaceutical market based on the criteria of foreign trade performance and detected the priorities of its growth, taking into consideration the synthesis of the state and trade regulation mechanisms.

PROSPECTS FOR THE PHYTOPREPARATIONS USE IN PARASITIC DISEASES

Today, 89% of all parasitic diseases are caused by helminthiasis. The annual morbidityof helminthiasis in Ukraine is 1333 cases per 100 thousand population. Their influenceleads to the development of multiavitaminosis with decreased appetite, body weight andresistance to adverse factors and metabolic disorders. Therefore, the issues of effectiveprevention and treatment are extremely relevant.Objective - to conduct a marketing analysis of the range of antiparasitic phytodrugsavailable on the Ukrainian pharmaceutical market and to determine the prospects fortheir further use in medicine.Material and methods. The analysis of the range of drugs, dietary supplements andmedicinal plant raw materials with anthelmintic action available on the pharmaceuticalmarket of Ukraine was conductedResults. 102 trade names in various dosage forms were identified, according to theanalysis of the range of drugs, dietary supplements and medicinal plant raw materialswith anthelmintic action available on the pharmaceutical market of Ukraine. It has beenfound that the range of drugs is mainly represented only by biologically active additives(97.06%). It should be noted that among the drugs there are both one-component dietarysupplements (18.63%) and combined (81.37%). The ratio of shares in the production ofantiparasitic drugs is approximately the same, domestic producers - 48.04% and foreignmanufacturers - 51.96%.Therefore, taking into account the topicality of the parasitic diseases problem, it isadvisable to use phytodrugs because of the action complexity at the expense of thebiologically active substances of plants, the lack of toxicity in contradistinction tosynthetic antiparasitic drugs.Conclusions. The represented phytodrugs and dietary supplements can be used asadditional means for pharmacotherapy improvement of the worm infestations, as well asfor recurrence prevention.

Theoretical and applied aspects of creating a unified information accounting system of pharmaceutical and medical products in Ukraine

In modern conditions of reforming the Ukrainian Health Care system based on the introduction of innovative digital information technologies, the development of a methodology for the computerization of pharmaceutical information exchange processes is relevant.
 The purpose of our study was to develop a methodology for creating a unified accounting system (UAS) of information on pharmaceutical and medical products (Ph&MP) in Ukraine (taking into account the current standards of computer systems for structuring and fixing information, as well as in accordance with international standards for automated identification of information about Ph&MP.
 The objects of the research were: scientific and specialized publications devoted to the issue of the implementation of a system of accounting and tracking of medical and health care in the EU, USA, Canada;pharmaceutical information with tracking and recording the established information flows in computer databases.The main research is based on the methodology of pharmaceutical informatics: creation of pharmaceutical computer databases, coding of pharmaceutical products. The method of system analysis processed publications on the types of Ph&MP encodings in the EU, USA, Canada.
 In the scientific work, the international standards for the sale of information in two-dimensional shaded codes of the DataMatrixECC 200 standard are highlighted, which is one of the information blocks on the basis of which the development of the UAS Ph&MP database structure should be based.The structure and interconnection of information blocks for the accounting of Ph&MP units using GTIN and serial numbers in the database of structural units of business entities of the pharmaceutical market of Ukraine have been developed.
 A systematic analysis of the types of Ph&MP encodings in the EU countries, the USA, and Canada has been carried out.Highlighted rational approaches to the formation of coding and accounting for Ph & MP, taking into account national characteristics. The basis of the integral structure of the UAS Ph&MP with basic information blocks has been developed.Approaches and principles to the methodology of its formation are given, taking into account the current standards of computer systems for the structuring and fixing of information, as well as in accordance with international standards for automated identification of information about Ph&MP. The requirements for the compliance of computer databases of structural units of business entities with modern standards for preserving pharmaceutical information necessary about medicines when accounting are presented.

Clinical and economic aspects of fibrates

Today statins are considered as first-line drugs for treating dyslipidemia. Fibrates also have a place in the treatment of dyslipidemia. Taking the above into account it is relevant to highlight the evidence of the effectiveness of these drugs in reducing unfavorable outcomes of cardiovascular diseases (CVD) and feasibility of using them in the complex therapy of dyslipidemia, as well as the study of the pharmacoeconomic characteristics of fibrates presented at the Ukrainian pharmaceutical market. Aim. To analyze the clinical efficacy of fibrates in reducing the consequences of CVD, as well as to study the range, price characteristics, availability and consumption of fibrates at the Ukrainian pharmaceutical market from 2017 to 2019.Materials and methods. The analysis of the evidence of the clinical efficacy of fibrates in patients with CVD and dyslipidemia was performed in accordance to systematic reviews from the international Pubmed database. The retrospective analysis of the assortment, prices, affordability and consumption of fibrates in Ukraine was conducted according to the data from the “PharmXplorer” analytical system of the “Morion” information retrieval company and the Compendium system. The economic affordability was assessed by the value of adequacy of paying capacity (Ca.s.), the consumption volumes – by DDDs (the number of average daily doses) and the number of packages sold during 2017-2019.Results. The evidence of the clinical efficacy of fibrates in reducing cardiovascular events in patients with CVD and DM type 2 with dyslipidemia were summarized in systematic reviews. Within 2017-2019, only 3 trade names (TNs) of foreign fenofibrate, which prices did not fluctuate significantly, were registered at the Ukrainian pharmaceutical market. Fenofibrate drug – Lipofen NS (Nobel, Turkey), caps., 250 mg, blister No. 30, was highly available for the Ukrainian consumer (Ca.s. less than 5.0 %), and Traikor® (Abbot Products GmbH, Germany), film coated tablets, 145 mg, blister No. 20 and No. 30 (Ca.s. more than 5.0 %), were moderately available. The dynamics of the sales growth (2.4 times) of fenofibrate packages in 2019 compared to 2017 was determined due to the growth in sales of Traikor® (film coated tablets, 145 mg, blister No. 20). The dynamics of the increase in consumption of fibrates by the value of DDDs was found. It generally corresponded to the dynamics of sales in the number of packages, but the consumption volumes were insignificant.Conclusions. The use of fibrates in patients with CVD and dyslipidemia for the primary or secondary prevention of risks of adverse cardiovascular events leads to their decrease; moreover, in patients with DM type 2 it helps to reduce the risk of nonfatal myocardial infarction (MI) development. The consumption of fibrates at the Ukrainian pharmaceutical market is insignificant, and is determined by their clinical efficacy and the place in the antihyperlipidemic therapy of CVD where statins prevail today.

The analysis of the evidence base of the clinical efficiency and safety of acyclovir for topical application

Herpes viruses are a family of DNA viruses, among them herpes simplex virus is the most common (HSV). An important task of modern medicine is effective and safe pharmacotherapy of viral diseases caused by HSV.Aim. To analyze the range of drugs for the topical application in the pharmacotherapy of HSV at the pharmaceutical market of Ukraine, as well as search the evidence base of acyclovir, the leader of the pharmaceutical market.Materials and methods. The analysis of the range of antiherpetic drugs for the topical application was performed according to the analytical system of the study of the pharmaceutical market of Ukraine “Pharmstandard” by the company “Morion”. To analyze the clinical efficiency and safety of the antiherpetic drug “Acyclovir”, the following well-known evidence-based databases were used: Cochrane Library, Trip Database, PubMed, Nice.Results. Antiherpetic drugs for the topical application at the pharmaceutical market of Ukraine for 2016-2018 were quantitatively represented from 17 to 20 TN based on 7 INNs, mainly by foreign manufacturers. Drugs of acyclovir were the most accessible and widely presented at the market. The search for the evidence base of acyclovir for the topical application made it possible to find 7 systematic reviews devoted to the treatment of herpes diseases in the evidence-based medicine databases. Numerous studies have shown that the topical treatment with the acyclovir HSV cream on the lips and in genital herpes is less effective than its systemic application. And the use of acyclovir ointments in the treatment of herpetic keratitis is not inferior in effectiveness to the reference drugs. Conclusions. The analysis of systematic reviews and meta-analyses has shown that the topical treatment with the acyclovir HSV cream is less effective than its systemic application. The effectiveness of the use of acyclovir ointments in the treatment of herpetic keratitis has also been proven.

PCV69 Consumption Volume of Plain Lipid Modifying Agents of the Statin Group on the Ukrainian Pharmaceutical Market during 2015-2018

PCV69 Consumption Volume of Plain Lipid Modifying Agents of the Statin Group on the Ukrainian Pharmaceutical Market during 2015-2018

MARKETING ANALYSIS OF THE RANGE OF ANTIPARASITIC DRUGS REPRESENTED ON THE PHARMACEUTICAL MARKET OF UKRAINE

Today, the parasitic diseases are the most common in the world and occupy one of the first places in terms of prevalence and economic losses. The reasons for this situation, according to experts, are low-quality epidemiologically dangerous water and low compliance with sanitary and hygienic standards. The problem of prevention and treatment remains relevant for almost all countries, including Ukraine. Objective - to conduct a marketing analysis of the range of the domestic pharmaceutical market of antiparasitic drugs. Material and methods. A marketing analysis was conducted using structural, logical, graphical, systematic and content analysis of data from the State Register of Drugs. Results. The first stage of the research was to study the range of antiparasitic drugs represented on the pharmaceutical market of Ukraine. It has been determined that in the pharmaceutical market, according to the State Register of Drugs of Ukraine, 22 names of anthelmintic drugs are registered. It has been established that the drugs, supplied to the domestic pharmaceutical market from every corner of the world, are 12 trade names, among which the leading positions in terms of supply are India and France (23% respectively). Antiparasitic drugs are presented in 3 dosage forms, among which the largest share are tablets - 65.2%, oral suspensions - 30.4%, the least in the pharmaceutical market are phytodrugs with antihelmintic activity (4.6%). The analysis of the registered antihelmintic drugs has shown that 95.6% of the study drugs are available by prescription. Conclusions. It has been found that the largest share of drugs are benzimidazole derivatives, which account for 47.8% of the total range of the studied drugs, the most common among anthelmintic drugs are dosage forms in tablets (65.2%).